How big is Verastem, Inc.?

As of Jun 18, Verastem, Inc. has a market capitalization of 291.78 million and reported net sales of 10.00 million with a net profit of -148.88 million over the latest four quarters. Shareholder's funds are at -28.89 million, and total assets amount to 101.54 million.

As of Jun 18, Verastem, Inc. has a market capitalization of 291.78 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 10.00 million, while the sum of net profit for the same period is -148.88 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -28.89 million, and the total assets amount to 101.54 million.

What does Verastem, Inc. do?

Verastem, Inc. is a biopharmaceutical company focused on developing cancer treatments, classified as a micro-cap with a market cap of approximately $291.78 million and a recent net profit of -$52 million. The company operates in the Pharmaceuticals & Biotechnology industry.

Overview:<BR>Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to improve outcomes for patients with cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 291.78 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 1.27<BR>Return on Equity: 404.74%<BR>Price to Book: -9.00<BR><BR>Contact Details:<BR>Address: 117 Kendrick St Ste 500, NEEDHAM MA: 02494-2730<BR>Tel: 1 781 2924200, 1 781 2924279<BR>Fax: 1 302 6555049<BR>Website: http://www.verastem.com/

Should I buy, sell or hold Verastem, Inc.?

Who are in the management team of Verastem, Inc.?

As of March 2022, the management team of Verastem, Inc. includes CEO Brian Stuglik and Lead Independent Director Dr. Michael Kauffman, along with Independent Directors Timothy Barberich, Gina Consylman, Alison Lawton, and Eric Rowinsky.

As of March 2022, the management team of Verastem, Inc. includes Mr. Brian Stuglik, who serves as the Chief Executive Officer and Director. Additionally, Dr. Michael Kauffman holds the position of Lead Independent Director. The board also comprises several Independent Directors: Mr. Timothy Barberich, Ms. Gina Consylman, Ms. Alison Lawton, and Dr. Eric Rowinsky.

Is Verastem, Inc. overvalued or undervalued?

As of August 8, 2024, Verastem, Inc. is rated as risky due to negative valuation ratios and performance metrics, indicating it may be overvalued despite a strong 1-year stock return of 252.03%.

As of 8 August 2024, the valuation grade for Verastem, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -10.88 and an EV to EBITDA of -2.38. Additionally, the negative ROCE and ROE further underscore the challenges facing the company.<BR><BR>In comparison to its peers, Verastem's P/E ratio is -4.0339, while Poseida Therapeutics, Inc. has a P/E of -15.2392 and MeiraGTx Holdings Plc stands at -3.8154, highlighting that Verastem is not the most attractive option within its sector. Despite recent strong returns, with a 1Y stock return of 252.03% compared to the S&P 500's 17.14%, the underlying valuation metrics suggest that caution is warranted.

Is Verastem, Inc. technically bullish or bearish?

As of October 31, 2025, Verastem, Inc. is in a bullish trend, supported by positive monthly MACD and KST indicators, despite mixed signals from Dow Theory and a mildly bearish weekly MACD, while outperforming the S&P 500 with a year-to-date return of 53.00% and a one-year return of 101.79%.

As of 31 October 2025, the technical trend for Verastem, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by the monthly MACD and KST indicators, both of which are bullish. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages also indicate a bullish trend. However, the weekly MACD is mildly bearish, and Dow Theory shows a mixed signal with mildly bullish weekly and mildly bearish monthly indicators. <BR><BR>In terms of performance, Verastem has outperformed the S&P 500 year-to-date with a return of 53.00% compared to 16.30%, and over the past year, it has significantly outperformed with a return of 101.79% against 19.89%.